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Summary
A single nucleotide transition within exon 5 of the 1-hexosaminidase a chain gene was identified in a
Puerto Rican patient with GM2-gangliosidosis B1 variant as the mutation responsible for the unusual en-
zymological characteristics of this variant (Gs33--'A; Arg178--'His) (the DN-allele). A total of seven patients
with enzymological characteristics of B1 variant have since been studied. They were Puerto Rican (DN),
Italian, French, Spanish, two patients of mixed ethnic origin (English/Italian/Hungarian and En-
glish/French/Azores), and a Czechoslovakian. In confirmation of our earlier finding based on screening
with allele-specific probes, all patients except the one from Czechoslovakia carried the same DN-allele. A
new point mutation found in this patient changed the same codon affected in the DN-allele (C532*T;
Argl78-Cys). An asymptomatic Japanese individual included as a control also carried one allele with the
DN-mutation. Site-directed mutagenesis and expression studies in COS I cells demonstrated that either of
the two point mutations abolishes the catalytic activity of the a subunit. The Spanish patient was homozy-
gous for the DN-allele, but others were all compound heterozygotes. The Puerto Rican patient was a com-
pound heterozygote with the DN-mutation in one allele and with the four-base insertion in exon 11, one
of the two mutations found in the classical Ashkenazi Jewish Tay-Sachs disease, in the other allele. Abnor-
malities of the other allele were not identified in all other compound heterozygous patients. In these pa-
tients, the level of mRNA derived from the other allele was variable, ranging from being undetectable to
being much lower than normal. This series of studies uncovered a new B1 variant mutation, confirmed our
preliminary finding that the DN-allele has a surprisingly wide geographic and ethnic distribution, and
pointed out the highly complex nature of the molecular genetics of this rare disorder. They also support
our working hypothesis that mutations responsible for the unique enzymological characteristics of the B1
variant should be located in or near exon 5 of the gene and that this region of the enzyme protein is criti-
cal for its catalytic function.
Introduction tion of GM2-ganglioside occurs in neurons through-
GM2-gangliosidosis occurs as the result of genetically out the body. Three major categories of GM2-ganglio-
defective catabolism of a monosialoganglioside, GM2 sidosis exist according to the genes that are defective;
(Sandhoff et al. 1989). Most forms of the disease are the a or 13 subunit of N-acetyl-13-hexosaminidase or the
rapidly progressive and fatal, and abnormal accumula- natural activator protein. Tay-Sachs disease, prevalent
in the Ashkenazi Jewish population, is the prototype
Received July 20, 1989; revision received September 20, 1989. of human GM2-gangliosidosis due to a defective a
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ant is caused by a major deletion in the 5' end of the
1-hexosaminidase a gene (Myerowitz and Hogikyan
1986, 1987). Almost all patients with classical infan-
tile Ashkenazi Tay-Sachs disease have one oftwo muta-
tions: (1) a splicing defect at the 5' donor site of intron
12 and (2) a four-base insertion within exon 11 (Arpaia
et al. 1988; Myerowitz 1988; Myerowitz and Costigan
1988; Ohno and Suzuki 1988a, 1988c). On the other
hand, there are variant forms of the disease in which
immunologically detectable but catalytically defective
enzyme protein is produced. A point mutation in the
coding sequence of 13-hexosaminidase a gene has re-
cently been identified (Nakano et al. 1988) in a patient
in whom the synthesized a subunit protein cannot be
transported intracellularly for normal processing ("in-
soluble a") (Proia and Neufeld 1982). More recently,
Navon and Proia (1989) and Paw et al. (1989) identified
a point mutation responsible for the adult Ashkenazi
Jewish form of the disease. Still unpublished is a transi-
tion from G to A at the last nucleotide of exon 5
identified in a Tunisian patient with late-infantile Tay-
Sachs disease with less than 10% residual activity of
0-hexosaminidase A (L. Poenaru, personal communi-
cation). Also among the cross-reactive material-positive
forms is the enzymologically unique B1 variant (Gold-
man et al. 1980; Li et al. 1981; Kytzia et al. 1983). B1
variant patients produce hexosaminidase A (a hetero-
dimer, a1) which appears normal catalytically when
tested with conventional chromogenic or fluorogenic
substrates, such as 4-methylumbelliferyl N-acetyl-
glucosaminide, which are split by an active site of the
13 subunit of the enzyme (Kytzia and Sandhoff 1985).
However, patients' hexosaminidase A is catalytical-
ly defective against both the natural lipid substrate,
GM2, and an artificial substrate, 4-methylumbelliferyl
N-acetylglucosamine 6-sulfate. These substrates are
hydrolyzed by the active site on the a subunit ofnormal
hexosaminidase A (Kytzia and Sandhoff 1985) which
is inactivated in patients' enzyme. Genetic complemen-
tation tests confirmed that the B1 variant is allelic to
other hexosaminidase a mutations (Sonderfeld et al.
1985). Fibroblasts from patients with this variant syn-
thesize and process an immunologically detectable a
subunit of an apparently normal size (Sonderfeld et al.
(1985). A specific point mutation in the coding sequence
of the 1-hexosaminidase a chain was earlier identified
in the first described patient with the B1 variant (Ohno
and Suzuki 1988b). The mutation resulted in an amino
acid change from arginine to histidine at residue 178
in the mutant enzyme. Computerized molecular model-
ing suggested drastic alterations in the three-dimensional
structure of the protein in the vicinity of the mutation,
consistent with the loss of catalytic activity. In the ab-
sence of the standardized nomenclature, this specific
mutation (a single nucleotide transition from G to A
at 533) will be referred to in this report as the DN-
allele. Ohno and Suzuki (1988b) hypothesized that this
region of the enzyme protein is important in defining
its catalytic activity and that patients with the unique
enzymological characteristics of the B1 variant might
have abnormalities in the same region, even though the
mutations may be different in differentpatients. A pre-
liminary study of six patients by allele-specific synthetic
oligonucleotide probes indicated a surprisingly wide
geographic and ethnic distribution of the DN-allele
(Tanaka et al. 1988). The present report describes results
of studies on a total of seven B1 variant patients, which
demonstrated that (1) a new point mutation, affecting
the same codon, is responsible for the disease in a
Czechoslovakian patient; (2) either of the point muta-
tions inactivates the catalytic activity of the enzyme;
(3) except for one Spanish patient, all patients were com-
pound heterozygotes; (4) the other allele in the original
Puerto Rican patient was one of the infantile Jewish
Tay-Sachs alleles, but other compound heterozygous
patients had neither of the infantile Jewish alleles; and
(5) the other alleles were mRNA positive in some pa-
tients and mRNA negative in others.
Material and Methods
Patients
Altogether, seven patients diagnosed enzymatically
as having the GM2-gangliosidosis B1 variant were in-
cluded in the present study: our original Puerto Rican
patient (Goldman et al. 1980); one patient each from
Italy, France, Spain, and Czechoslovakia; and two pa-
tients of mixed ethnic background (the maternal grand-
parents of one patient were English-Scottish and Ger-
man-English, and the paternal grandparents were Italian
and Hungarian, respectively; and the other patient was
of English/French background with grandparents of
both sides from the Azores). The patient from France
was included in one of our earlier reports (Kytzia et
al. 1983), and the one from Czechoslovakia is also in
the literature (Conzelmann et al. 1985). The pertinent
clinical and enzymological information on these pa-
tients is given in table 1. Our preliminary study included
all of these patients except case 7 (Tanaka et al. 1988).
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CASE SEX BACKGROUND Onset Death Total Activity %A Sulfated Substrate
lb ... M French 2 years, 1 mo 7 years, 1 mo 107 50% .21
2C .... M Czechoslovakia 8 mo 1 year, 11 mo 101 30% .20
3 .... F Italian "Juvenile" 71.4 72% .13
4 .... F Spanishd 2-3 years 13 years, 2 mo 96.3 61% .22
e .... M Puerto Rican 11 mo 4 years, 8 mo 132 51% .31
6 .... M English/Italian/Hungarian 2-3 years Still alive 90.9 62% .19
7 .... M English/French/Azoresf 4 years Still alive 90.5 49% .04
NOTE.-There was no positive record of consanguinity for any of the patients.
a Normal control activities (n = 7) for the nonsulfated and sulfated substrates were 154 ± 21.4 (A = 65 ± 11%) and 18.7 ± 6.5,
respectively.
b Reference: Kytzia et al. (1983).
c Reference: Conzelmann et al. (1985).
d Parents were from the same village.
e References: Goldman et al. (1980), Kytzia et al (1983), and Ohno and Suzuki (1988c).
f Grandparents of both sides were from the Azores.
Commercial Materials
Bethesda Research Laboratories (Gaithersburg, MD),
Boerhinger Mannheim (Indianapolis), Pharmacia (Pis-
cataway, NJ), International Biotechnologies Inc. (New
Haven, CT), and New England Biolab (Beverley, MA)
were the main sources for enzymes, reagents, and other
molecular biological supplies. Radioisotopes were ob-
tained from ICN Radiochemicals (Irvine, CA). 4-Meth-
ylumbelliferyl 1-N-acetylglucosaminide was purchased
from Sigma Chemical Co. (St. Louis), and 4-methyl-
umbelliferyl P-N-acetylglucosamine 6-sulfate was from
the HSC Research Development Corp. (Toronto). Trans-
formed African green monkey kidney cells (COS I) were
purchased from the American Type Culture Collection
(Rockville, MD). Sources for nonstandard materials will
be indicated below as appropriate.
Fibroblast Cultures
For all patients, cultured fibroblasts were used as the
source materials for the study. Besides our original pa-
tient, individual cell lines were shipped to Chapel Hill,
NC, from Boston, Bonn, and Lyon. They were main-
tained and propagated under the standard conditions
of the laboratory for a minimum of a few weeks before
harvesting.
Enzymatic Assays
IB-Hexosaminidase A and B activities were determined
on total homogenates of cultured fibroblasts. 4-Methyl-
umbelliferyl O-N-acetylglucosaminide was used as sub-
strate for differential assays for the A and B isozymes
by the heat inactivation method, and 4-methylumbel-
liferyl I3-N-acetylglucosamine 6-sulfate was used for di-
rect assessment of the activity of the A isozyme (Suzuki
1987). The amount of protein was determined essen-
tially by the method of Lowry et al. (1951) with BSA
as the standard.
DNA Polymerase Chain-Reaction and DNA Sequence
Analysis
Genomic DNA was isolated according to the stan-
dard procedure (Maniatis et al. 1982). Two 20-mer
primers were synthesized for the polymerase chain-
reaction procedure for amplification of genomic se-
quences (Kogan et al. 1987; Wong et al. 1987; Oste
1988; Stoflet et al. 1988). One of them was within in-
tron 3, approximately 85 bases upstream of exon 4 (5'-
GCTCTGCTACATTGAGAACC), and the other was
within intron 5, about 30 bases downstream of exon
5 (5'-CTGTCCGTTGCTCCATCACC). Since intron 4
is approximately 0.5 kb, the distance between the two
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primers in the gene was about 800 bp. The protocol
for the reaction was as follows: The target sequence
was amplified in a 100-gl reaction vol containing 5 jg
genomic DNA in 50 mM Tris-HCl, pH 8.3, 1.5 mM
MgCl2, 0.2 mM each of dNTP, and 1 pM of each
primer in a siliconized microcentrifuge tube. Samples
were heated at 940C for 6 min, centrifuged momentar-
ily, and annealed at 550C for 3 min. Two and a half
units of Taq polymerase was added, and the samples
were incubated at 720C for 3.5 min for extension with
an overlayer of 100 g1 mineral oil. The manual cycling
profile was 550C for 2.5 min (annealing), 720C for 3.5
min (extension), and 941C for 1.5 min (denaturation).
Usually, the extension reaction was repeated 40 times.
Taq polymerase (2.5 units) and the primers (30 pmol
each) were added at the 20th cycle, and Taq polymer-
ase only (2.5 units) was added at the 30th cycle. The
procedure was terminated after the 41st extension reac-
tion, which was run for 7 min. In later experiments,
an automated thermal cycler apparatus was used for
the polymerase chain-reaction, instead of the manual
procedure described above. In the automated procedure,
the cycling times for annealing, extension, and dena-
turation were 2, 3, and 1 min, respectively, and 3.5 units
of Taq polymerase was added only at the beginning of
the cycling procedure. Taq polymerase was purchased
from Cetus-Perkin Elmer Corp. (Norwalk, CT). After
amplification, a portion of the reaction mixture was
subjected to agarose-gel electrophoresis to ascertain
presence of the amplified 800-bp sequence. The re-
mainder was digested with BamHI and StuI. A BamHI
site is located in intron 4, and the StuI site is within
intron 5 near its 5' end. Thus, the digestion generated
a BamHI-StuI fragment that included most of the in-
tron 4 sequence, the entire exon 5, and a short segment
of intron 5. The fragment was subcloned into appro-
priate M13 vectors, and the sequence analysis was car-
ried out by the Sanger dideoxy chain-termination
method (Sanger et al. 1977) with the 17-mer sequenc-
ing primer and 35S-labeled dATP (Biggin et al. 1983).
The DNA polymerase used for sequencing was either
the Klenow enzyme or the T7 polymerase (Sequenase;
US Biochemical Corp., Cleveland).
Expression of the Catalytic Activity in the COS I System
The catalytic activity of the enzyme protein produced
by the 1-hexosaminidase a cDNA clone was expressed
in the COS I cell system. The normal hexosaminidase
a cDNA clone (Myerowitz et al. 1985) was digested
with NarI to leave only 60 bases of 5'-untranslated se-
quence above the initiation codon and was subcloned
into a eukaryotic expression vector, pSVL. This was
the same strategy used recently by Navon and Proia
(1989). The COS I cells were transfected by the DEAE-
dextran-mediated procedure (Cullen 1987). ISHexo-
saminidase activities were assayed 48 h after transfec-
tion with 4-methylumbelliferyl ,B-N-acetylglucosaminide
and 4-methylumbelliferyl j-N-acetylglucosamine 6-sul-
fate, as described above. For expression of the clones
with the DN mutation, both the native full-length mu-
tant clone obtained from the patient's fibroblasts and
the clone generated from the normal cDNA by site-
directed mutagenesis were examined. For the new B1
variant mutation, only the mutation generated in the
normal cDNA by site-directed mutagenesis was exam-
ined, because native full-length mutant cDNA was not
available. Entire experiments were repeated at least once
more and often a few times, with duplicate plates in
each experiment to insure reproducibility of the results.
Site-directed Mutagenesis
Either of the B1 variant mutations (Gs33-A or
C532--T) were introduced into the normal 0-hexos-
aminidase a cDNA clone by site-directed mutagenesis
using a commercially available mutagenesis kit (Muta-
Gene Phargemid In Vitro Mutagenesis Kit; Bio-Rad
Labs, Richmond, CA) according to the procedure
provided by the manufacturer. The vector was a phar-
gemid, pTZ18UamP+, and the host E. coli were
CC2MV119Odut+ ,ung+ ,cp- ,amp- and CJ236dut- ,ung- ,c-
p + ,amp - . The transformants were analyzed by sequenc-
ing with an antisense 15-mer primer that hybridized
at 15 bases downstream of the mutagenized nucleotide
(5'-GTCCAGGATGCTAGAGAG). The efficiency of the
mutagenesis was approximately 75%. Correctly mu-
tagenized clones were subcloned into pSVL for subse-
quent expression experiments in the COS I cells as
above.
Screening for the Infantile Ashkenazi Jewish Alleles with
Single Polymerase Chain-Reaction and Allele-specific Probes
The strategy is depicted in figure 1. Two primers were
used to amplify a segment of I-hexosaminidase a chain
gene that included both the regions of the four-base
insertion in exon 11 and the exon 12-intron 12 junc-
tional mutation found in the classical infantile Ash-
kenazi Jewish Tay-Sachs disease. The 5' primer was
within exon 11 at the same segment as used by My-
erowitz and Costigan (1988) (5'-GTGTGGCGAGAG-
GATATTCCA). The 3' primer was from the intron 12
sequence, approximately 80 bases downstream of the
5' donor site (Ohno and Suzuki 1988a) (5'-AGACCC-
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axon 112Intron 12 exon 12 Intron 12
DriMer .------------- *- approx. 530 bp---- Rrimer 2
Primer 1: 58-GTGTGGCGAGAGGATATTCCA Caxon 11)
Primer 2: 51-AGACCCAATCCCATCTAGCCA (intron 12)
Probes: 59-GAKCCGTATATCCTATGGC (insertion, normal)
51-GAACCGTATATCTATCCTA (insertion mutant)
5. -CCAGGCTCTGGTMAGGGTTTT (splicing-defect, normal)
5'-CCAGGCTCTGCTAAGGGTTTT (splicing defects mutant)
Figure I Strategy for screening for the two classical infantile Ashkenazi Jewish Tay-Sachs disease alleles. A single polymerase chain
reaction amplifies the segment of the gene that includes both sites for the two mutations known to occur in the infantile Ashkenazi disease.
Then two pairs of allele-specific probes are used to detect the normal and mutant sequences by dot hybridization.
AATCCCATCTAGCCA). The amplified segment was
approximately 530 bp, including two-thirds of exon
11, all of both intron 11 and exon 12, and about 80
bases of intron 12. Two pairs of allele-specific oligonu-
cleotide probes were synthesized, one pair of normal
and mutant sequences for the four-base insertion and
one pair of normal and mutant sequences for the
splicing-defect mutations: insertion, 5'-GAACCGTATA-
TCCTATGGC (normal) and 5'-GAACCGTATATC
TATCCTA (mutant); splicing defect, 5'-CCAGGCTCT-
GGTAAGGGTTTT (normal) and 5'-CCAGGCTCT-
GCTAAGGGTTTT (mutant).
The amplified sequence was examined by agarose-
gel electrophoresis, and the quantity was estimated. Ap-
proximately 10 ng amplified products was applied to
Gene Screen Plus membrane (NEN Research Products,
Boston) and dried. The prehybridization was in 6 x
SSC, 5 x Denhardt's solution, 0.05% sodium pyro-
phosphate, 0.5% SDS, and 100 ig heat-denatured
salmon-sperm DNA/ml at 370C for 1 h. Hybridiza-
tion was in the same mixture, except for 1 x Denhardt's
solution without SDS and the addition of 50 pmol
probes labeled at the 5' end with [y-32P]ATP and poly-
nucleotide kinase. The specific activity of the probes
was generally in the range of 1.5-2.0 x 104
cpm/pmol. Hybridization was continued overnight with
gentle shaking, at 440C for the probes for the splicing
defect and at 370C for the probes for the four-base in-
sertion. These temperatures were chosen as
[Td-(16-20)]OC. The membranes were washed in 6
x SSC, 0.05% sodium pyrophosphate four times for
10 min each at room temperature and then were washed
twice more for 15 min each in the same solution but
at [Td -5]0C. The dried membrane was exposed to X-
ray film at -70'C with the Cronex intensifying screen.
Screening for Stable mRNA Derived from the
Non-BI Allele
Since six of the seven B1 variant patients examined
were compound heterozygotes and since five did not
possess either of the infantile Ashkenazi Jewish alleles,
attempts were made to detect mRNA molecules which
do not contain the B1 variant sequences. Total RNA
was isolated, by the standard procedure (Ausubel et al.
1989), from cultured fibroblasts. Some of the normal
control RNA was isolated from leukocytes prepared
from freshly drawn blood. The polymerase chain-
reaction was carried out with two primers that were
complementary to normal mRNA segments flanking
the exon 5 sequence: 5'-GTCCAGGATGCTAGAGAG
and 5'-TCCGAGAGGGGAGACCAGCGG. The first
reaction was with the downstream primer and avian
myeloblastosis virus (AMV) reverse transcriptase (Pro-
mega Corp., Madison, WI), according to the method
of Sarkar and Sommer (1988) but with additional 4
mM sodium pyrophosphate and 1 unit RNAsin/jl in
the reaction mixture. Then the remainder of the am-
plification procedure was essentially the same as de-
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scribed above. Three 21-mer oligonucleotides all cen-
tered around nucleotide 533 were used as allele-specific
probes: the normal sequence (nucleotide 532 = C;
nucleotide 533 = G), theDN sequence (nucleotide 533
= A), and the new B1 variant sequence (nucleotide 532
= T). Dot blotting, hybridization, and autoradiogra-
phy were done in manners essentially similar to those
described above for the genomic DNA screening.
Results
The results of the polymerase chain-reaction and sub-
sequent sequencing of the amplified gene segments were
consistent with the analyses with the oligonucleotide
probes (Tanaka et al. 1988). The complete sequence
of exon 5 and the flanking sequences of intron 4 and
intron 5 could be determined by this procedure. In all
patients, at least six-and, in some cases, as many as
a dozen-subcloned fragments were sequenced for
statistical reliability. In addition, whenever a sequence
which was neither normal nor of the DN-allele was
encountered, the entire procedure, from the amplifica-
tion ofgenomicDNA through sequencing, was repeated
in order to exclude possible artifacts due to polymerase
errors. As to be discussed later, this precaution proved
to be critical. Two different mutations were identified
within exon 5 (figs. 2 and 3). The DN-allele was pres-
ent in six patients. The only exception was the patient
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lele. The mutation in this patient was a single nucleo-
tide transition in the same codon as in the DN-allele.
The transition in this case was in nucleotide 532, from
the normal C to T in the mutant. This mutation in the
first base of the codon results in a point mutation of
amino acid 178, from arginine to cysteine, in contrast
to the DN-mutation, which changes the same arginine
to histidine because of the transition of the second
nucleotide of the codon.
The normal exon 5 and flanking sequence were also
detected in all patients except in the Spanish patient
(case 4), indicating frequent compound heterozygos-
ity, as expected for this rare genetic condition. Only
the DN-allele sequence was found in the Spanish pa-
tient. When this fact is considered together with the
finding with the oligonucleotide probes (Tanaka et al.
1988), it is likely that this patient was homozygous for
the DN-allele.
The results of expression of the catalytic activity in
the COS I cells are summarized in figure 4. Transfec-
tion with the normal 0-hexosaminidase a clone resulted
in twofold and six- to sevenfold increases of the base-
line activity with the nonsulfated and sulfated substrates,
respectively. These findings are consistent with I-hex-
osaminidase S (aa) being primarily responsible for the
increase in the catalytic activity. Excess production of
the a subunit in the system is expected to generate ex-
cess of the S isozyme, which has very low catalytic ac-
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Figure 2 Mutations in GM2-gangliosidosis B1 variant: sequence analysis of exon 5 of the amplified 0-hexosaminidase a gene. A,
DN-allele. B, normal gene sequence. C, Sequence in the Czechoslovakian patient. The sequences represent the noncoding strand, with the
bottom of the gel being the 5' side. The area shown corresponds to nucleotides 523-543 in fig. 3.
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exon 4 1 exon 5
451 GAG GGC ACA[TTC TTT ATC AAC AAG ACT GAG ATT GAG GAC TTT CCC
151 Glu Gly Thr[Phe Phe Ile Asn Lys Thr Glu Ile Glu Asp Phe Pro
496 CGC TTT CCT CAC CGG GGC TTG CTG TTG GAT ACA TCT






541 CTG CCA CTC TCT AGC ATC CTG GAC
181 Leu Pro Leu Ser Ser Ile Leu Asp
ACT CTG]GAT GTC
Thr Leu]Asp Val
exon 5 0 exon 6
ATG GCG TAC
MET Ala Tyr
Figure 3 Exon S and flanking regions of exons 4 and 6 sequences of 1-hexosaminidase a gene, showing the location of the two muta-
tions responsible for the B1 variant phenotype. The boundaries of exon S and introns are indicated by square brackets.
ward the sulfated substrate. The clones with either of
the B1 variant mutations, natural or generated by muta-
genesis, completely failed, with either of the substrates,
to increase the catalytic activities above the. baseline.


















ing both regions of the two mutations responsible for
the classical infantile Ashkenazi Jewish Tay-Sachs dis-
ease and subsequent screening with oligonucleotides
specific for the respective alleles provided a rapid and
reliable procedure for detection of these mutant genes
Mock Normal DN-N DN-M CZ-M Mock Normal DN-N DN-M CZ-M
4-MU GIcNAc 4-MU GIcNAc-SO4
Figure 4 Expression of the catalytic activity in COS I cells. The methodological details are described in the text. DN-N = DN-mutant
cDNA isolated from the patient; DN-M and CZ-M = mutant cDNAs corresponding to the DN-mutation and to that in the Czechoslovakian




(fig. 5). None of the six compound heterozygous pa-
tients had the gene with the splicing defect. However,
our original Puerto Rican patient was heterozygous with
the four-base insertion. Thus, except for both the Span-
ish patient (case 4), who is likely to be a B1 homozygote,
and the Puerto Rican patient (case 5), the abnormali-
ties of the other allele in these patients remain un-
identified. Incidental but informative observations were
made regarding specimens from patients with various
clinical phenotypes of Tay-Sachs disease who were in-
cluded in the experiment (fig. 5). Three patients with
infantile Tay-Sachs disease-Japanese, a black, and a
"Caucasian"- had neither of the Jewish alleles. One
3-year-old patient recorded as "Caucasian" (GM0221)
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Figure 5 Screening for the two classical infantile Ashkenazi
Jewish Tay-Sachs disease alleles. The strategy is depicted in fig. 1.
Methodological details are described in the text. Each sample was
dot-blotted in duplicate. Among the seven B1 variant patients, only
case 5 (Puerto Rican) has the four-base insertion in the other allele.
Identification of other samples are as follows: NK = a Japanese,
16 mo; 502B = Ashkenazi Jewish, 11 mo; 515A = Ashkenazi Jew-
ish, 1 year; 0077 = a black, 1 year; 0221 = "Caucasian;' 3 years,
0527 = "Caucasian;' 15 mo; 3052 = Ashkenazi Jewish, 24 years,
obligate heterozygous carrier. The figure was prepared from a single
X-ray film, although for a clearer presentation samples were rear-
ranged from the original 12 samples/row.
three Jewish patients, GM502B was a compound het-
erozygote with both the splicing defect and the four-
base insertion, confirming the previous results (My-
erowitz 1988; Myerowitz and Costigan 1988; Ohno
and Suzuki 1988a, 1988c). The other two Jewish indi-
viduals, GM0515A and GM3052, both carried the four-
base insertion in one allele but no splicing defect in
the other allele. GM3052 is an obligate heterozygous
carrier of a Jewish patient known to carry both of the
abnormal alleles. In agreement with Myerowitz and
Costigan (1988), the results on GM0515A indicate that
this 1-year-old Jewish patient carries the four-base in-
sertion in one allele and another, yet to be identified
abnormality in the other. While many of these obser-
vations are confirmatory of previous results, they dem-
onstrate usefulness of both the single amplification and
the subsequent screening with the allele-specific probes
as a rapid diagnostic procedure.
Since the screening of the amplified genomic sequence
showed five of the seven patients to have unidentified
abnormality in the other allele, attempts were made to
detect mRNA that has the normal sequence in the re-
gion of the B1 mutations. A positive signal would indi-
cate presence of mRNA derived from the other allele.
The results were complex (fig. 6). Relatively even den-
sity for the mutant probes for all samples assured that
semiquantitative comparison was possible among the
samples for the normal sequence. As expected, mRNA
with the normal sequence around nucleotides 532 and
533 was not detected either in the Spanish patient, who
is homozygous for the DN-allele, or in the Puerto Ri-
can patient, who has the four-base insertion in the other
allele, which is known to be essentially mRNA nega-
tive. In addition to these two cases, no signal was visi-
ble for the normal sequence in the French patient (case
1). Very faint but visible signals were obtained for cases
2 and 6. The signals for cases 3 and 7 were moderately
strong but still much less than those of the normal con-
trol, even after the double gene dosage in the normal
control is considered. Unexpectedly, an asymptomatic
Japanese individual included as a control appeared to
carry the DN-mutation in one allele, further indicating
the widespread nature of this particular mutation (fig. 6).
Discussion
When we identified the point mutation in our origi-
nal Puerto Rican patient with the GM2-gangliosidosis
B1 variant, we postulated that, in view of the rather
unique enzymological characteristics of the variant, mu-



















Figure 6 Levels ofdetectable ,B-hexosaminidase a chain mRNA.
Methodological details are described in the text. Each sample was
dot-blotted in duplicate. All Bi variant patients produce mRNA with
either of the mutations identified for the variant (DN = GS33 to A;
CZ = CS32 to T). As expected, no mRNA with the normal sequence
in this segment is detectable in case 4 (homozygous for the DN-allele)
and case 5 (the other allele has the Ashkenazi four-base insertion,
known to be mRNA negative). Although much less than normal,
mRNA from the other allele is clearly present at significant amounts
in cases 3 and 7 and is barely detectable in cases 2 and 6. mRNA
from the other allele could not be detected in case 1. Control 3 is
an asymptomaticJapanese individual who appears to carry one DN-
allele.
patients might be in the same region ofthe enzyme pro-
tein (Ohno and Suzuki 1988b). We anticipated, how-
ever, that the specific mutations in individual patients
will probably be different, because the disease is very
rare and is distributed widely in different ethnic groups
in the world. The findings on the Czechoslovakian pa-
tient support our hypothesis. This patient had a new
point mutation not just within exon 5 but in fact in
the same codon. As a result, Arg178 in normal enzyme
protein is changed to cysteine in this case instead of
to histidine as in the DN-allele. Experiments with site-
directed mutagenesis and expression in the COS I cells
showed that either of these mutations abolishes the cata-
lytic activity. Thus, Arg17s must be critical for the cata-
lytic activity of the enzyme. On the other hand, the
enzymological characteristic of the Czechoslovakian pa-
tient was different from that of the other patients in
that I-hexosaminidase A activity toward 4-methyl-
umbelliferyl l-glucosaminide was partially deficient,
while it was essentially normal in other patients (table 1).
The wide geographic and ethnic distribution of the
DN-allele was first indicated by allele-specific oligonu-
cleotide screening (Tanaka et al. 1988) and has now
been confirmed by actual sequencing. The same DN-mu-
tation is responsible for six of the seven B1 variant pa-
tients so far examined, the exception being the Czechos-
lovakian patient. Furthermore, the DN-mutation was
also found in an asymptomatic Japanese individual by
the oligonucleotide screening. This findingwas surpris-
ing and was somewhat contrary to our prediction, even
though G--A/C-,T transitions are much more com-
mon than transversions. Although three patients might
be considered as having a Hispanic background (pa-
tients 4, 5, and 7), a common origin of these individu-
als is not obvious.
Only in two of the seven patients examined could
the gene abnormalities in both alleles be identified. The
Spanish patient is the only known B1 variant patient
to date who is homozygous for the DN-allele. This is
consistent with the family history that the parents of
this patient are from the same village in Spain, although
there is no positive record of consanguinity. The Puerto
Rican patient was a compound heterozygote of the
DN-allele and the four-base insertion of the infantile
Ashkenazi Jewish allele. Even in the other compound
heterozygous individuals, the other allele is a priori ab-
normal, since they would not otherwise have been symp-
tomatic. Whatever the nature of the abnormality in the
other allele might be, we found at least exon 5 and the
flanking intron sequences to be normal in these patients.
If the other allele is of both mRNA-positive and cross-
reacting material-positive type, a mixture of two ab-
normal a chains will be generated, possibly resulting
in complex enzymological characteristics. If, on the
other hand, it is of the mRNA-negative type, there will
be only one type of enzyme protein derived from the
B1 variant alleles. The enzymological characteristics of
these patients were generally typical of the B1 variant-
normal or moderately low hexosaminidase A activity
toward the unsulfated fluorogenic substrate and dis-
proportionately defective activity toward GM2-
ganglioside and/or the sulfated artificial substrate. Three
possibilities can account for these findings: (1) the other
allele may not be producing any stable enzyme protein;
(2) the protein product of the other allele is totally in-
active catalytically, or (3) mutations outside exon 5 re-
gion can produce a mutant protein that has enzymo-
logical characteristics indistinguishable from that of the
B1 variant. The levels ofmRNA derived from the other
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allele were so low in cases 1, 2, and 6 that the quantity
of the enzyme protein would be probably insignificant
even if it is stable. Only in cases 3 and 7 were there
sufficiently high levels of mRNA from the other allele
to potentially result in a significant quantity of another
mutant enzyme protein, if it is stable. these considera-
tions clearly point to the genetic complexities and the
intrinsic limitation of the enzymological classification
of this class of genetic disorders.
Our original B1 patient was first diagnosed as an atyp-
ical case of AB variant (GM2 activator deficiency) be-
cause of the normal I-hexosaminidase A and B activi-
ties with the fluorogenic substrate (Goldman et al.
1980). One of the atypical features was the slightly later
onset and slower progression of the disease compared
with those of patients having typical infantile Tay-Sachs
disease. From the limited number of patients examined
in the present study, B1 variant patients with the DN-
allele (Arg17s--His) are generally in the late-infantile
to juvenile age groups (table 1). The Czechoslovakian
patient who has the new B1 variant mutation (Arg17s >
Cys), however, had the clinical onset and course more
typical of a patient having infantile Tay-Sachs disease.
As more B1 variant mutations are expected in the fu-
ture, clinical and enzymological features of the B1 vari-
ant will certainly be complex, and no generalization
is possible. For example, some of the patients in the
literature who have been described as having juvenile
GM2-gangliosidosis with partial deficiency of 0-hexos-
aminidase A may well have had mutations in the same
region of the I-hexosaminidase a chain (Suzuki et al.
1970; Suzuki and Suzuki 1970; Zerfowski and Sandhoff
1974). Previously, B1 variant was thought to occur when
a mutation in the a subunit gene abolishes its catalytic
activity toward the nonsulfated substrate but retains the
activity toward both the natural substrate, GM2-
ganglioside, and the sulfated substrate. This notion is
not quite correct conceptually. In view of the different
nature of the active sites on the a and 13 subunits (Kyt-
zia and Sandhoff 1985), the enzymological character-
istics of the B1 variant would be expected whenever
a mutation in the a subunit results in a stable but cata-
lytically inactive a chain that is still capable of nor-
mally associating with the IB subunit to form the A iso-
zyme. Under such circumstances, the activity toward
4-methylumbelliferyl 13-glucosaminide will be normal
because the A isozyme includes the normal catalytic
site on the 13 subunit.
During the course of the polymerase chain-reaction
and sequencing, we encountered a few artifactual "mu-
tations." Two of them were found in multiple clones
after cloning of the amplified sequence into the M13
vector. Therefore, whenever we found abnormal se-
quences, the entire procedure was repeated, from the
step of amplification of the genomic DNA through se-
quencing. Our experience indicates that this precau-
tion is critical in order to exclude abnormalities due
to polymerase errors, when amplified segments are
cloned into vectors for subsequent sequencing.
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